Literature DB >> 6454515

The specificity of suppressor T cells induced by chronic Mycobacterium avium infection in mice.

S R Watson, F M Collins.   

Abstract

Normal mice infected intravenously with 10(6) or 10(8) viable M. avium develop persistent infections of the lungs, liver and spleen. The liver and spleen counts remained relatively constant whereas those for the lung slowly increased until eventually some of the animals began to die as a result of the infection. None of the heavily infected mice developed delayed hypersensitivity (DTH) to the M. avium cytoplasmic protein antigen (CPA). Spleen cells harvested at increasing time periods after the M. avium infection were tested for their blastogenic responsiveness to PHA and M. avium CPA. The presence of suppressor T cells within the heavily infected spleens was demonstrated by means of cell-mixing experiments before and after treatment of the anergic spleen cells with anti-Thy-1.2 antiserum and complement. The specificity of the suppressor T cells was measured in terms of their ability to depress responsiveness to sheep erythrocytes and an allograft challenge. Initially, the suppressor T cell population affected all of the T cell-mediated responses but as the infection progressed, so the non-specific host responses tended to return gradually towards normal, whereas the specific M. avium CPA-mediated suppression persisted largely unchanged.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6454515      PMCID: PMC1537120     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Suppressor cells in experimentally trypanosomiasis.

Authors:  A N Jayawardena; B H Waksman
Journal:  Nature       Date:  1977-02-10       Impact factor: 49.962

2.  Immunopotentiation with BCG. I. Immune response to different strains and preparations.

Authors:  G B Mackaness; D J Auclair; P H Lagrange
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

Review 3.  Infection, anergy and cell-mediated immunity.

Authors:  F S Kantor
Journal:  N Engl J Med       Date:  1975-03-20       Impact factor: 91.245

4.  Restoration of delayed hypersensitivity to sheep erythrocytes by thymosin treatment of T-cell-depleted mice.

Authors:  F M Collins; N E Morrison
Journal:  Infect Immun       Date:  1976-02       Impact factor: 3.441

5.  The evolution of immunosuppressive cell populations in experimental mycobacterial infection.

Authors:  W E Bullock; E M Carlson; R K Gershon
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

6.  Development of suppressor T-cells in Mycobacterium habana-infected mice.

Authors:  S R Watson; F M Collins
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

7.  Bacterial lipopolysaccharide activates suppressor B lymphocytes.

Authors:  S Koenig; M K Hoffmann
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

8.  Development of suppressor T cells in mice heavily infected with mycobacteria.

Authors:  S R Watson; F M Collins
Journal:  Immunology       Date:  1980-03       Impact factor: 7.397

9.  Immune response to persistent mycobacterial infection in mice.

Authors:  F M Collins; N E Morrison; V Montalbine
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

10.  T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites.

Authors:  R J North; D P Kirstein
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

View more
  15 in total

1.  The role of macrophage activation and of Bcg-encoded macrophage function(s) in the control of Mycobacterium avium infection in mice.

Authors:  R Appelberg; A M Sarmento
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

2.  Two types of suppressor T cells that inhibit delayed-type hypersensitivity to Mycobacterium intracellulare in mice.

Authors:  R M Nakamura; Y Goto; K Kitamura; T Tokunaga
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

3.  Immune response to atypical mycobacteria: immunocompetence of heavily infected mice measured in vivo fails to substantiate immunosuppression data obtained in vitro.

Authors:  I M Orme; F M Collins
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

4.  Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria.

Authors:  I M Orme; F M Collins
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

5.  Macrophage uptake and retention of radiolabeled glycopeptidolipid antigens associated with the superficial L1 layer of Mycobacterium intracellulare serovar 20.

Authors:  L C Hooper; M M Johnson; V R Khera; W W Barrow
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

6.  Comparison of the effect of various stimuli on the leishmaniacidal capacity of human monocytes in vitro.

Authors:  J Passwell; R Shor; G Keren; G Messer; J El-On
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

7.  Genetic control of resistance to Mycobacterium intracellulare infection in mice.

Authors:  Y Goto; R M Nakamura; H Takahashi; T Tokunaga
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

8.  T cell proliferation in Mycobacterium lepraemurium infection. I. Lack of correlation between antigen-specific proliferation of Lyt 1 + 23- cells and resistance in lethal infections.

Authors:  R C Mathew; J Curtis; J L Turk
Journal:  Immunology       Date:  1984-01       Impact factor: 7.397

9.  Human monocytes infected with Leishmania amastigotes enhance lymphocyte proliferation.

Authors:  J Passwell; R Shor; G Keren; J el-On
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

10.  Mechanism of immunosuppression in leprosy: presence of suppressor factor(s) from macrophages of lepromatous patients.

Authors:  P R Salgame; P R Mahadevan; N H Antia
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.